<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

2 min read

ESGCT 30th Annual Congress, October 24-27

ESGCT 30th Annual Congress, October 24-27

Booth: #4

Date: October 24-27, 2023

Location: Brussels, Belgium

Event website: https://www.esgctcongress.com

 

Mark your calendar! Don't miss Giuliana Vallanti's presentation

Our AGC Biologics' VP of Development & Global R&D for Cell & Gene Therapies, Giuliana Vallanti, will be presenting during the event.

Don't miss her presentation "Building Flexible End-to-End Cell Therapy Manufacturing Strategies" during Session 10d: Manufacturing (BEL PARALLEL) - 8:30 on Friday, October 27. We hope to see you there! 

Two of our SME's will also be presenting at poster sessions starting Wednesday, October 25 in Gare Maritime. Francesca Rossetti will be in P241 from 17:00-18:15 and Luca Crippa will be in P244 18:15-19:30.
 
As well as, Thursday, October 26 in Gar Maritime. Luca Crippa will be in P244 from 19:30-20:30 and Francesca Rossetti will be in P241 from 20:30-21:30. 

MEET OUR TEAM

Would you like to talk with one of our team members? Interested in learning more about our global network and capabilities? Click the button below or email one of our attending representatives at the event to set up a meeting.

REQUEST A MEETING

You can also reach out directly to our experts attending the show

Giuliana Vallanti
VP, Development & Global R&D C&G
Email  me
Francesca Rossetti
Director, Analytical Method Development
Email  me
Luca Crippa
Sr. Manager, Downstream Vector Development
Email  me
Matteo Valle
Proposal Manager, Business Development
Email  me
Mattia Ferrarese
Associate Proposal Manager, Business Development
Email  me

Explore our AAV & LVV Platforms

BravoAAV™ and ProntoLVV™ are end-to-end platforms offering a proprietary GOI backbone and plug-and-play templates for any project. Our services include proprietary plasmids, in-house analytical panels, master cell banks, pre-qualified processes and fill and finish services.  

Our new templated adeno-associated viral vector platform.

 Learn about Bravo

Our new templated lentiviral vector platform.
 

Learn about our cell and gene therapy services 

Cell Therapy Production and Manufacturing

AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.  

Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting. 

Learn more about our overall cell therapy offering 

 

Plasmid DNA (pDNA) Materials 

To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing. 

Learn more about our Plasmid offering

 

Viral Vector Production and Manufacturing 

AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products. 

Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house. 

Discover more about our viral vector services 

 

Fill out the form below to request a meeting during the event